Resectable Eyelid Squamous Cell Carcinoma
1 clinical trials · Condition
◉ Watch Resectable Eyelid Squamous Cell Carcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer (NCT06568172) | National Cancer Institute (NCI) | 2025-02-18 |
Track Resectable Eyelid Squamous Cell Carcinoma automatically
Every clearance here is in the API, with alerts when new ones post.